On May 19 and 20, Vienna was once again the venue for the international life sciences scene. BioEquity Europe is the most important investor meeting in Europe and was held for the first time in Vienna. 25 Austrian companies participated; 14 of them had the opportunity to present themselves to the attending investors. In total there were around 500 participants on site. This high-profile event was held in Vienna this year, because of an initiative from the life science platform LISAvienna operated by the Vienna Business Agency and the Austria Wirtschaftsservice GmbH (aws).
Within the framework of the BioEquity Europe, innovative high-tech companies strive to get international venture capital. Business developers of the major pharmaceutical companies who are on the lookout for licensing deals were present in addition to the private equity industry.
In Vienna, around 400 companies and 25 research institutions are active in the life sciences industry. They employ over 35,000 employees, and the annual turnover of the Vienna-based companies amounts to more than 9 billion Euros. The Vienna Business Agency and the aws are promoting this innovative industry with targeted funding offers, individual counseling and a high-quality research infrastructure.